{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:40:07Z","timestamp":1787024407321,"version":"build-2736575974"},"reference-count":18,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BLCTT"],"DOI":"10.2147\/blctt.s398809","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:30:13Z","timestamp":1696293013000},"page":"59-65","source":"Crossref","is-referenced-by-count":4,"title":["90Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: A Report of 5 Cases"],"prefix":"10.2147","volume":"Volume 13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8296-2961","authenticated-orcid":true,"given":"Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Baidoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-094X","authenticated-orcid":true,"given":"Han W","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":true,"given":"Muhamad","family":"Alhaj Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1002\/cncr.24522","volume":"115","author":"Jain","year":"2009","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11899-021-00637-1","volume":"16","author":"Small","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"ref5","unstructured":"Emmanouilides, CE. Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin\u2019s lymphoma (NHL). Proc Am Soc Clin Oncol. 2003;22:595."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3121\/cmr.3.3.157","volume":"3","author":"Rao","year":"2005","journal-title":"Clin Med Res"},{"key":"ref7","first-page":"p. 457","volume":"2","author":"Knox","year":"1996","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1172\/JCI110005","volume":"67","author":"Nadler","year":"1981","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.clml.2022.03.004","volume":"22","author":"Alhaj Moustafa","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1188\/02.CJON.144-148","volume":"6","author":"Hendrix","year":"2002","journal-title":"Clin J Oncol Nurs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref12","first-page":"1317","volume":"40","author":"DeNardo","year":"1999","journal-title":"J Nucl Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2706::AID-CNCR49>3.0.CO;2-D","volume":"80","author":"DeNardo","year":"1997","journal-title":"Cancer"},{"key":"ref14","first-page":"1","volume":"88","author":"Kaminski","year":"1999","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"p. 2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","volume":"25","author":"Czuczman","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2019-129391","volume":"2019","author":"Alhaj Moustafa","year":"2019","journal-title":"Am Soc Hematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Blood and Lymphatic Cancer: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=93219","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=93219","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:30:18Z","timestamp":1696293018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/90yttrium-ibritumomab-tiuxetan-zevalin-for-the-treatment-of-chronic-ly-peer-reviewed-fulltext-article-BLCTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":18,"URL":"https:\/\/doi.org\/10.2147\/blctt.s398809","relation":{},"ISSN":["1179-9889"],"issn-type":[{"value":"1179-9889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}